AKRO•benzinga•
Evercore ISI Group Upgrades Akero Therapeutics to Outperform, Raises Price Target to $50
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on September 14, 2022 by benzinga